The new TB vaccine is prepared by spray drying method, which overcomes the problem of refrigeration. This new approach gives better preserving ability and protection against the disease. The vaccine is cost effective and easily transportable.
The study, by researchers at the University of North Carolina-Chapel Hill, the Aeras Global TB Vaccine Foundation, MEND South Africa, the Harvard School of Public Health and School of Engineering and Applied Sciences, found that the aerosol version of TB vaccine, administered directly to the lungs as an oral mist, offered significantly better protection against the disease in experimental animals than a comparable dose of the traditional injected vaccine.
The new technique offers several potential advantages over conventional freezing procedures such as it could provide a low-cost, needle-free TB treatment that is highly stable at room temperature.
"While most new TB vaccines continue to call for needle injection, our vaccine could provide safer, more consistent protection by eliminating these injections and the need for refrigerated storage," said David Edwards, the Gordon McKay Professor of the Practice of Biomedical Engineering in Harvard's School of Engineering and Applied Sciences.
Barry R. Bloom, dean of the Harvard School of Public Health: "Tuberculosis is one of the most resistant and challenging diseases to protect against, and the successful results of aerosol delivery using nanoparticle technology offers a potentially new platform for immunization.
"Were the animal results here confirmed in human studies, this technology could be used not only for TB vaccines, but those protecting against other infectious diseases as well," he added.